188 related articles for article (PubMed ID: 37491951)
1. Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T-cells (CAR-T): A comprehensive review on incidence, risk factors and current management.
Galli E; Fresa A; Bellesi S; Metafuni E; Maiolo E; Pansini I; Frioni F; Autore F; Limongiello MA; Innocenti I; Giammarco S; Chiusolo P; Zini G; Sorà F
Eur J Haematol; 2024 Feb; 112(2):184-196. PubMed ID: 37491951
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
[TBL] [Abstract][Full Text] [Related]
3. Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy.
Wudhikarn K; Perales MA
Bone Marrow Transplant; 2022 Oct; 57(10):1477-1488. PubMed ID: 35840746
[TBL] [Abstract][Full Text] [Related]
4. Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions.
Wat J; Barmettler S
J Allergy Clin Immunol Pract; 2022 Feb; 10(2):460-466. PubMed ID: 34757064
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
Abramson JS; Lunning M; Palomba ML
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia development soon after anti-CD19 chimeric antigen receptor T-cell infusion in a patient with refractory diffuse large B-cell lymphoma and pre-existing clonal hematopoiesis.
Falini L; Venanzi A; Tini V; Innocente A; Ballanti S; Saldi S; Sivolella S; Pierini A; Aristei C; Tiacci E; Perriello VM; Falini B
Haematologica; 2023 Jan; 108(1):290-294. PubMed ID: 35899391
[No Abstract] [Full Text] [Related]
8. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.
Rejeski K; Perez A; Iacoboni G; Blumenberg V; Bücklein VL; Völkl S; Penack O; Albanyan O; Stock S; Müller F; Karschnia P; Petrera A; Reid K; Faramand R; Davila ML; Modi K; Dean EA; Bachmeier C; von Bergwelt-Baildon M; Locke FL; Bethge W; Bullinger L; Mackensen A; Barba P; Jain MD; Subklewe M
Sci Adv; 2023 Sep; 9(38):eadg3919. PubMed ID: 37738350
[TBL] [Abstract][Full Text] [Related]
9. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
[TBL] [Abstract][Full Text] [Related]
10. Late Effects after Chimeric Antigen Receptor T cell Therapy for Lymphoid Malignancies.
Chakraborty R; Hill BT; Majeed A; Majhail NS
Transplant Cell Ther; 2021 Mar; 27(3):222-229. PubMed ID: 33928266
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis.
Reinhardt B; Lee P; Sasine JP
Cells; 2023 Feb; 12(4):. PubMed ID: 36831198
[TBL] [Abstract][Full Text] [Related]
12.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
13. Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors.
Xia Y; Zhang J; Li J; Zhang L; Li J; Fan L; Chen L
Ann Med; 2022 Dec; 54(1):2951-2965. PubMed ID: 36382675
[TBL] [Abstract][Full Text] [Related]
14. [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Alsuliman T; Drieu La Rochelle L; Campidelli A; Duléry R; Fayard A; Mamez AC; Mear JB; Schneider PO; Trevet A; Vicente C; Yakoub-Agha I
Bull Cancer; 2021 Dec; 108(12S):S65-S71. PubMed ID: 33678408
[TBL] [Abstract][Full Text] [Related]
15. Beyond CD19 CAR-T cells in lymphoma.
Leung WK; Ayanambakkam A; Heslop HE; Hill LC
Curr Opin Immunol; 2022 Feb; 74():46-52. PubMed ID: 34800921
[TBL] [Abstract][Full Text] [Related]
16. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J
J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094
[TBL] [Abstract][Full Text] [Related]
17. Impact of
Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML
J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
19. CAR T-cell Therapy Meets Clonal Hematopoiesis.
Uslu U; June CH
Blood Cancer Discov; 2022 Sep; 3(5):382-384. PubMed ID: 35896010
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
